THAR Form 3: Stetz Discloses Options and Warrants With Vesting Details

Rhea-AI Filing Summary

Gary S. Stetz, a director of Tharimmune, Inc. (THAR), filed an initial Form 3 reporting beneficial ownership arising from an event on 04/28/2025. He directly owns 101,351 shares of common stock. He holds a stock option for 50,000 shares exercisable (with 25,000 shares vested on grant and 25,000 vesting on 08/04/2026) at an exercise price of $1.33. He also holds Series A warrants for 101,351 shares (strike $1.29, expiring 12/13/2030) and Series B warrants for 50,675 shares (strike $3.00, expiring 12/13/2030). The form is signed on 08/20/2025.

Positive

• Director status disclosed: Gary S. Stetz is identified as a director of Tharimmune, Inc.
• Immediate option vesting: 25,000 of the 50,000 stock options vested on grant as stated.
• Complete derivative detail: Exercise prices and expiration dates are explicitly provided for options and both warrant series.

Negative

• None.

Insights

Financial Analyst

TL;DR Routine initial ownership disclosure by a director; option and warrant positions specified with exercise prices and expirations.

The filing is a standard Form 3 reporting a director's direct holdings in common stock plus derivative positions. Key figures are explicitly stated: 101,351 common shares, a 50,000-share stock option with a $1.33 exercise price and specified vesting, and two warrant series (101,351 shares at $1.29 and 50,675 shares at $3.00) expiring 12/13/2030. These details clarify potential dilution if derivatives are exercised but the filing contains no additional financial performance or transaction context.

Corporate Governance Expert

TL;DR Disclosure shows director equity and derivative incentives; vesting schedule and direct ownership are clearly documented.

This Form 3 cleanly reports the director's ownership and incentive instruments. The immediate vesting of 25,000 option shares is explicitly noted, with the remainder vesting on 08/04/2026. All holdings are reported as direct. The filing provides necessary transparency for insider ownership but contains no information on any policy, agreement, or transaction that initiated these holdings beyond the event date.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Stetz Gary S.

(Last) (First) (Middle)

C/O THARIMMUNE, INC.

34 SHREWSBURY AVE., SUITE 1C

(Street)

RED BANK NJ 07701

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
04/28/2025

3. Issuer Name and Ticker or Trading Symbol
Tharimmune, Inc. [ THAR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	101,351	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	08/04/2035	Common Stock	50,000	$1.33	D
Series A Warrants	12/13/2025	12/13/2030	Common Stock	101,351	$1.29	D
Series B Warrants	12/13/2025	12/13/2030	Common Stock	50,675	$3	D

Explanation of Responses:

1. 25,000 of the options vest on date of grant and 25,000 vest on August 4, 2026.

	/s/ Gary S. Stetz	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What securities did Gary S. Stetz report on Form 3 for THAR?

The Form 3 reports 101,351 common shares, a stock option for 50,000 shares (exercise price $1.33), Series A warrants for 101,351 shares (strike $1.29), and Series B warrants for 50,675 shares (strike $3.00).

When was the event requiring the Form 3 filing dated?

The date of the event requiring the statement is 04/28/2025.

What are the exercise and expiration details for the stock option reported?

The stock option covers 50,000 shares with an exercise price of $1.33; 25,000 shares vested on grant and 25,000 vest on 08/04/2026. The option lists an exercisable/expiration reference of 08/04/2035.

What are the expiration dates for the reported warrants?

Both Series A and Series B warrants expire on 12/13/2030.

When was the Form 3 signed by the reporting person?

The Form 3 is signed by /s/ Gary S. Stetz on 08/20/2025.